When and how to restore β-cell function?

International Congress Series

Volumn 1303, Issue , 2007, Pages 138-145

  Pancani, Francesca ^a   Lupi, Roberto ^a   Miccoli, Roberto ^a   Marchetti, Piero ^a   Del Prato, Stefano ^a  

^a CISANELLO HOSPITAL   (Italy)

Author keywords

Cell function; Cell mass; Insulin secretion

Indexed keywords

EID: 34447648942     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2007.03.029     Document Type: Article

References (57)

1. Stumvoll M., and Haring H. Insulin resistance and insulin sensitizers. Horm. Res. 55 Suppl 2 (2001) 3-13
2. Leahy J.L. Pathogenesis of type 2 diabetes mellitus. Arch. Med. Res. 36 (2005) 197-209
3. Abdul-Ghani M.A., et al. Insulin secretion and insulin action in subjects with impaired fasting and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study (VEGAS). Diabetes (2006) 1430-1435
4. American Diabetes Association. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study (UKPDS) Group. Diabetes 44 (1995) 1249-1258
5. Levy J., et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet. Med. 15 (1998) 290-296
6. Bagust A., and Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM 96 (2003) 281-288
7. Del Prato S., and Tiengo A. The importance of first phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes/Metab. Res. Rev. 17 (2001) 164-174
8. Butler A.E., et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
9. Cretti A., et al. Assessment of beta-cell function during the oral glucose tolerance test by a minimal model of insulin secretion. Eur. J. Clin. Invest. 31 (2001) 405-416
10. Altshuler D., et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26 (2000) 76-80
11. Gloyn A.L., et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 52 (2003) 568-572
12. Grant S.F., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 38 (2006) 320-323
13. Scott L.J., et al. Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 55 (2006) 2649-2653
14. Chandak G.R., et al. Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population. Diabetologia 50 (2007) 63-67
15. Cauchi S., Froguel P., et al. TCF7L2 variation predicts hyperglycemia incidence in a French general population: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. Diabetes 55 (2006) 3189-3192
16. Florez J.C., et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. NEJM 355 (2006) 241-250
17. Munoz, et al. Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes 55 (2006) 3630-3634
18. Damcott C.M., et al. Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 55 (2006) 2654-2659
19. Del Prato S., and Marchetti P. Beta-and alpha-cell dysfunction in type 2 diabetes. Horm. Metab. Res. 36 (2004) 775-781
20. Taylor R., et al. Direct assessment of liver glycogen storage by 13C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects. J. Clin. Invest. 97 (1996) 126-132
21. Bernard-Kargar C., and Ktorza A. Endocrine pancreas plasticity under physiological and pathological conditions. Diabetes 50 Suppl 1 (2001) S30-S35
22. Del Prato S., et al. β-Cell mass plasticity in type 2 diabetes. Diabetes Obes. Metab. 6 (2004) 319-331
23. Chandra J., et al. Role of apoptosis in pancreatic beta-cell death in diabetes. Diabetes 50 Suppl 1 (2001) S44-S47
24. Mandrup-Poulsen T. Beta-cell apoptosis: stimuli and signaling. Diabetes 50 Suppl 1 (2001) S58-S63
25. Flier S., et al. Evidence for a circulating islet cell growth factor in insulin-resistant states. PNAS 98 (2001) 7475-7480
26. Bonner-Weir S. Life and death of the pancreatic β-cells. Trends Endocrinol. Metab. 11 9 (2000) 375-378
27. Bonner-Weir S. Beta-cell turnover: its assessment and implications. Diabetes 50 Suppl 1 (2001) S20-S24
28. Matthews D.R., et al. Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet. Med. 15 4 (1998) 297-303
29. Maedler K., et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J. Clin. Endocrinol. Metab. 90 (2005) 501-506
30. Elrick H., et al. Plasma insulin responses to oral and intravenous glucose administration. J. Clin. Endocrinol. Metab. 24 (1964) 1076-1082
31. Nauck M., et al. Reduced incretin effect in type 2 diabetes. Diabetologia 29 (1986) 46-54
32. Kreymann B., et al. Glucagon-like peptide 1 7-36: a physiological incretin in man. Lancet 2 (1987) 1300-1304
33. Matsuyama T., et al. Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone. Diabetes Res. Clin. Pract. 5 (1988) 281-284
34. Nauck M., et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin dependent) diabetic patients. Diabetologia 36 (1993) 741-744
35. Mentlein R., Gallwitz B., and Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214 (1993) 829-835
36. Kieffer T.J., McIntosh C.H., and Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (1995) 3585-3596
37. Want L.L., et al. Exenatide and pramlintide: new therapies for diabetes. Int. J. Clin. Pract. 60 12 (2006) 1522-1523
38. Buse J.B., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 11 (2004) 2628-2635
39. DeFronzo R.A., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 5 (2005) 1092-1100
40. Kendall D.M., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 5 (2005) 1083-1091
41. Pratley R.E., et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm. Metab. Res. 38 6 (2006) 423-428
42. Mari A., et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed ß-cell function in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 90 8 (2005) 4888-4894
43. Ahren B., et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28 8 (2005) 1936-1940
44. Wang Q., et al. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 47 3 (2004) 478-487
45. Bai L., Meredith G., and Tuch B.E. Glucagon-like peptide-1 enhances production of insulin in insulin-producing cells derived from mouse embryonic stem cells. J. Endocrinol. 186 2 (2005) 343-352
46. Leiter L.A. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in type 2 diabetes. Diabet. Med. 22 (2005) 963-972
47. Lebovitz H.E., et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 86 (2001) 280-288
48. Wolffenbuttel B.H., et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet. Med. 17 (2000) 40-47
49. Einhorn D., et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin. Ther. 22 (2000) 1395-1409
50. Jones T.A., et al. Addition of rosiglitazone to metformin is effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes. Metab. 5 (2003) 163-170
51. Miyazaki Y., et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24 (2001) 710-719
52. Porter L.E., et al. Rosiglitazone reduces proinsulin/insulin ratio and improves b-cell function in type 2 diabetes. Diabetologia 43 Suppl. 1 (2000) A192
53. Wallace T.M., Levy J.C., and Matthews D.R. An increase in insulin sensitivity and basal β-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet. Med. 21 (2004) 568-576
54. R. Lupi, et al. Personal data.
55. Finegood D.T., and Topp B. β-Cell deterioration-prospects for reversal or prevention. Diabetes Obes. Metab. 3 (2001) S20-S27
56. Azen S.P., et al. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin. Trials 19 (1998) 217-231
57. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096-105.